Steward of the Early Biological Response Decision Protocol

EBR Institute.

Advancing early-stage R&D from commitment bias
to disciplined capital governance.

We do not predict success.

We govern commitment when outcomes are not yet visible.

Request Founding Fellow Access Explore the EBR Protocol
ebrprotocol.org ebrinstitute.org ebrprotocol.com ebrinstitute.com

The Capital Escalation Gap

Where value is lost in early R&D.

Biological silence precedes management action by months — sometimes years. The gap between signal availability and governance decision is where capital escalation becomes irreversible.

FIGURE 1.1 $0 50M 100M 150M M0 M6 M12 M18 M24 M30 BIOLOGICAL SIGNAL available at M12 CAPITAL COMMITMENT continues escalating GOVERNANCE ACTION — M22 10-month decision gap Biological signal Capital commitment Value destruction zone

Figure 1.1: The Capital Escalation Gap.
82% of value loss occurs between signal availability and governance action.
Source: EBR Decision Casebook v3.x — Shadow validation across independent pharmaceutical and translational datasets.

Structure

The EBR Ecosystem.

The EBR ecosystem is intentionally structured to separate standard, stewardship, and implementation. Each component serves a distinct role.

01
Governance — The Standard
EBR Protocol

The canonical definition of the Early Biological Response Decision Protocol — a non-predictive methodology for early biological decision governance.

ebrprotocol.org →
02
Stewardship — The Institution
EBR Institute

The organizational steward responsible for protocol definition and versioning, governance principles, and evidence standards. The Institute does not sell products or consulting services.

ebrinstitute.org →
03
Application Layer
Implementations

Operational applications of EBR-compliant decision reviews, including structured early decision audits. No implementation defines or modifies the protocol.

ebrprotocol.com →
04
Institutional Interface
Integration

Frameworks for integration with pharma, biotech, and investment governance structures. Designed for institutional-grade R&D oversight.

ebrinstitute.com →

The Problem

The Commitment Trap.

~90%
of early-stage R&D programs fail before reaching late-stage clinical development.
82%
of value loss occurs after early biological signals are already present — during the governance gap.

Early-stage R&D is rarely limited by lack of data. It is limited by how long decisions remain unmade.

The gap between biological silence and managerial decision is where most value is lost.

Commitment often persists well beyond the point where decision-relevant signals are already present — driven by organizational inertia, sunk cost bias, and delayed governance.

Capital escalation frequently continues after biological commitment has already failed to materialize. The EBR Protocol was developed to close this gap.

The EBR Protocol

A governance standard
for biological uncertainty.

The Early Biological Response Decision Protocol is a governance standard for early-stage biological decision-making under uncertainty. It is non-predictive by design.

Non-predictive by Design

The protocol does not estimate probabilities or future outcomes. Decisions are bounded to evidence present within the early commitment window.

Methodologically Bounded

Decisions are made strictly on evidence available within the early commitment window — no extrapolation, no narrative override.

Deterministic Decision Space

Every decision resolves to one of three outcomes. The protocol governs when commitment is justified — not whether outcomes will succeed.

STOP
Early de-escalation — commitment does not meet governance threshold.
MODIFY
Corrective iteration — conditional continuation with defined parameters.
CONTINUE
Accelerated commitment — evidence supports full programme progression.

Evidence Stack

Structured retrospective evidence.

The EBR Protocol is supported by structured, retrospective evidence across independent pharmaceutical and translational datasets. Detailed materials are available upon request under NDA.

EBR_CASEBOOK_V3.1.PDF
Shadow validation across independent pharmaceutical and translational datasets. Decision Casebook documenting 40+ reviewed programmes.
[RESTRICTED ACCESS]
EBR_FAILURE_AUTOPSIES_2024.PDF
Identification of delayed stop points and escalation pathologies in historical R&D programmes. Failure autopsy methodology documentation.
[RESTRICTED ACCESS]
EBR_DLT_ANALYSIS_V2.PDF
Decision Lead Time Analysis — quantification of decision latency between early biological signal availability and actual governance actions.
[RESTRICTED ACCESS]
EBR_EXECUTIVE_SUMMARY.PDF
Protocol overview and institutional positioning document. Available to qualified institutional contacts under NDA. Contact the Institute to initiate access.
[NDA REQUIRED]
Download Executive Summary — NDA required. Institutional contacts only.

Advisory & Stewardship

The Founding Fellows.

The EBR Institute is guided by a circle of senior industry leaders, former C-level executives, and biomedical scientists committed to advancing discipline in early-stage R&D decision-making.

Participation is based on stewardship, not endorsement.

Founding Fellow
Former VP R&D — Major Pharma
Founding Fellow
Former CSO — Biotech, Listed
Founding Fellow
Investment Partner — Life Sciences
Founding Fellow
Professor of Translational Medicine
MEMBERSHIP CONFIDENTIAL — NAMES DISCLOSED UPON INSTITUTIONAL ENGAGEMENT
Join as a Founding Fellow
EBR

Institutional Positioning

What the Institute is — and is not.

The EBR Institute does not operate as
  • a technology vendor
  • a consulting firm
  • a regulatory authority
It functions as a steward of decision governance — maintaining standards, not products.
Methodological consistency
Ensuring the protocol definition remains stable, versioned, and resistant to implementation drift.
Auditability of early decisions
Providing the evidence infrastructure for retrospective review of governance actions.
Protocol integrity over time
The Institute's role is analogous to institutions that maintain standards rather than sell products.